Barrington Research Reiterates AtriCure

by Benzinga Staff
February 28, 2012 5:40 PM | 28 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Barrington Reserach reiterated its AtriCure (NASDAQ: ATRC) Outperform rating in a research report published today. Barrington Research has a $17 price target on AtriCure.In the report, Barrington Research stated, "We are reiterating our OUTPERFORM rating given our belief that ATRC's hybrid ablation procedure will be the standard of care procedure for the less invasive surgical management of persistent and permanent AF and that ATRC's LAA clip will become standard of care for the epicardial treatment of the LAA."Shares of AtriCure closed today at $10.71, up 3.48% from Monday's market close.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorReiterationAnalyst RatingsBarrington Research

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.